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Pancreatic cystic neoplasms (PCNs) represent a heterogeneous
group of lesions with varying malignant potential. There is sig-
nificant variation in the reported prevalence of PCNs, ranging
from<1% to 24.3%, however, they are increasingly being inci-
dentally detected due to widespread use of cross-sectional ima-
ging including computed tomography (CT) and magnetic reso-
nance imaging (MRI) [1, 2].
PCNs present a significant management dilemma. Certain
lesions such as serous cystadenomas (SCAs) exhibit very low
malignant potential. On the other hand, mucinous cystic neo-
plasms (MCNs), branch-duct intraductal papillary mucinous
neoplasms (IPMNs), and main-duct IPMNs are reported to har-
bor malignant potential of 10% to 20%, 15% to 25%, and 40%
to 50%, respectively [3–5]. Although surgical resection is cura-
tive in the absence of invasive carcinoma, surgery can also be
associated with significant morbidity and potential mortality
[6].
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Background and study aims The American Gastroenterological
Association (AGA) recently published guidelines for the manage-
ment of asymptomatic pancreatic cystic neoplasms (PCNs). We
aimed to evaluate the diagnostic characteristics of the AGA guide-
lines in appropriately recommending surgery for malignant PCNs.
Patients and methods A retrospective multicenter study was per-
formed of patients who underwent endoscopic ultrasound (EUS) for
evaluation of PCNs who ultimately underwent surgical resection
from 2004–2014. Demographics, EUS characteristics, fine-needle
aspiration (FNA) results, type of resection, and final pathologic di-
agnosis were recorded. Patients were categorized into 2 groups
(surgery or surveillance) based on what the AGA guidelines would
have recommended. Performance characteristics for the diagnosis
of cancer or high-grade dysplasia (HGD) on surgical pathology
were calculated.
Results Three hundred patients underwent surgical resection for
PCNs, of whom the AGA guidelines would have recommended sur-
gery in 121 (40.3%) and surveillance in 179 (59.7%) patients.
Among patients recommended for surgery, 45 (37.2%) had cancer,
whereas 76 (62.8%) had no cancer/HGD. Among patients recom-
mended for surveillance, 170 (95.0%) had no cancer/HGD; how-
ever, 9 (5.0%) patients had cancer that would have been missed.
For the finding of cancer/HGD on surgical pathology, the AGA
guidelines had 83.3% sensitivity (95% CI 70.7–92.1), 69.1% speci-
ficity (95% CI 62.9–74.8), 37.2% positive predictive value (95% CI
28.6–46.4), 95.0% negative predictive value (95% CI 90.7–97.7),
and 71.7% accuracy (95% CI 67.4–74.6).
Conclusions The 2015 AGA guidelines would have resulted in 60%
fewer patients being referred for surgical resection, and accurately
recommended surveillance in 95% of patients with asymptomatic
PCNs. Future prospective studies are required to validate these
guidelines.
Meeting presentations: Presented in part at Digestive Diseases
Week 2016
Original article
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Endoscopic ultrasound (EUS) is increasingly utilized due to
its ability to provide valuable information in differentiating mu-
cinous from non-mucinous PCNs and identify malignant cysts
[7]. Certain EUS features have been shown to correlate with
malignant potential, such as presence of a solid component or
mural nodule, thickened cyst walls, and a dilated main pancre-
atic duct [8]. EUS also allows for fine-needle aspiration (FNA) for
cyst fluid analysis and cytology, the latter of which can be high-
ly specific for detection of malignancy [9]. Various studies have
also evaluated the utility of cyst fluid tumor markers such as
carcinoembryonic antigen (CEA) in diagnosis of mucinous or
pre-malignant cysts [9].
However, despite these apparent advantages, EUS morphol-
ogy, cyst fluid analysis, and cytologic analysis are each insuffi-
cient alone to diagnose potentially malignant lesions [9–12].
Multiple novel biomarkers have been evaluated such as micro-
RNA as well as somatic mutations in the GNAS and KRAS genes
and appear promising in accurate detection of potentially
malignant lesions; however, these tests have yet to be fully va-
lidated for routine clinical use [13, 14]. Due to the uncertainties
regarding the management of PCNs, multiple consensus guide-
lines have been developed, including the Sendai guidelines in
2006, Fukuoka guidelines in 2012, and European guidelines in
2013 [15–17]. While these guidelines have been validated in
various studies [18–20], application of these guidelines has
been shown to result in unnecessary surgery for many benign
low-risk cysts, while missing other cysts with high-grade dys-
plasia or associated invasive cancer [19, 21–24].
Recently, the American Gastroenterological Association
(AGA) published guidelines for the management of asympto-
matic PCNs [25, 26]. The 2015 AGA guidelines call for a much
less aggressive surveillance regimen than the Sendai and Fu-
kuoka guidelines (▶Table 1). In this study, we seek to evaluate
the diagnostic performance of the AGA guidelines for identifi-
cation of high-grade dysplasia (HGD) or cancer in patients with
PCNs who had previously undergone EUS with or without FNA
followed by surgical resection.
▶ Table 1 Comparison of Sendai (2006), Fukuoka (2012), and AGA (2015) guidelines on management of pancreatic cystic neoplasms.
Issues 2006 Sendai guidelines 2012 Fukuoka guidelines 2015 AGA guidelines
Surveillance Cyst < 1cm: MRI annually Cyst > 3 cm without high-risk stigmata1 or Less than 2 high-risk features2: repeat MRI
Cyst 1–2 cm without high-
risk stigmata3: surveillance
every 6–12 months
worrisome features4: alternate EUS with
MRI every 3 –6 months
in 1 year, then every 2 years until year 5, then
stop surveillance
Cyst 2–3 cm without high-
risk stigmata3: surveillance
every 3–6 months
Cyst 2–3 cm without high-risk stigmata1 or
worrisome features4: EUS in 3–6 months
then lengthen interval and alternate with
MRI
Two or more high-risk features2: EUS-FNA, if
negative, then repeat MRI in 1 year, then every
2 years until year 5, then stop surveillance
Cyst 1–2 cm without high-risk stigmata1 or
worrisome features4: CT/MRI yearly for 2
years, then lengthen interval if no change
Discontinue surveillance when patient is no
longer a surgical candidate
Cyst < 1cm: CT/MRI in 2–3 years
Surgical referral Cyst > 3 cm Any high-risk stigmata1 At least 2 high-risk features2 confirmed by
EUS-FNA, or concerning cytology
Cyst 1–3 cm with any
high-risk stigmata3
Worrisome features3 on EUS
Cyst > 3 cm in young/fit patients
Cyst 2–3 cm in young/fit patients
Main duct IPMN Surgical resection Surgical resection Not evaluated
Postoperative
surveillance
No cancer: no surveillance MCN: no surveillance No cancer or HGD: no surveillance
Cancer: MRI or CT every
6 months
IPMN with positive margins: MRI every
6 months
Cancer or HGD: MRI every 2 years
IPMN with negative margins: MRI at 2 and
5 years
AGA, American Gastroenterological Association; CT, computed tomography; EUS-FNA, endoscopic ultrasonography with fine-needle aspiration; HGD, high-grade
dysplasia; IPMN, intraductal papillary mucinous neoplasm; MRI, magnetic resonance imaging
1 High-risk stigmata (Fukuoka 2012): obstructive jaundice, solid component, dilated main pancreatic duct≥10mm
2 High-risk features (AGA 2015): cyst≥3 cm, solid component, dilated main pancreatic duct
3 High-risk stigmata (Sendai 2006): mural nodules, dilated main pancreatic duct, positive cytology
4 Worrisome features (Fukuoka 2012): pancreatitis, cyst≥3 cm, thickened cyst wall, main pancreatic duct 5–9mm, nonenhancing mural nodule, abrupt change in
caliber of pancreatic duct with distal pancreatic atrophy




We performed a retrospective cohort study at four academic
tertiary care referral centers with extensive pancreatic surgical
experience and interest in pancreatic cystic neoplasms. These
include the Ronald Reagan University of California Los Angeles
Medical Center (Los Angeles, CA), the Barnes-Jewish Hospital
at Washington University in St. Louis (St. Louis, MO), the Uni-
versity of Colorado Anschutz Medical Center (Aurora, CO), and
Northwestern Memorial Hospital (Chicago, IL). Institutional Re-
view Board approval was obtained at each institution.
Inclusion and exclusion criteria
We included all patients who were evaluated for a PCN with EUS
with or without FNA from 2004–2014 who subsequently un-
derwent surgical resection. Prior to 2006, participating institu-
tions referred patients to surgery based on interpretation of
cross-sectional imaging, EUS morphologic characteristics, and
cyst fluid analysis. Each of the participating centers subse-
quently incorporated the Sendai guidelines from 2006–2012,
and the Fukuoka guidelines from 2012 until the time of this
study analysis.
We excluded patients with PCNs who were referred directly
to surgery without undergoing EUS; patients who underwent
surgery for non-neoplastic pancreatic cysts such as pseudo-
cysts; patients who underwent surgery for cystic lesions that
were specifically not evaluated in the AGA guidelines such as
main duct IPMNs, solid pseudopapillary neoplasms, cystic neu-
roendocrine tumors, and cystic degeneration of pancreatic
ductal adenocarcinomas; and patients who underwent serial
surveillance with EUS or cross-sectional imaging who did not
ultimately undergo surgery. Finally, patients were excluded if
data could not be accurately obtained from review of their re-
cords.
Demographics and clinical history
For all patients meeting inclusion criteria, electronic medical
records were reviewed. EUS was performed according to the
current standard of care by experienced endosonographers.
FNA samples were obtained using a variety of endoscopic nee-
dles at the discretion of the endosonographer. Surgical data
were collected by review of operative reports. FNA and surgical
pathology data were obtained by review of the final pathology
reports generated by a gastrointestinal pathologist.
Data collected included basic demographics including age
and sex, presence of high-risk features on EUS as defined by
the AGA guidelines (cyst size≥3cm, presence of solid cyst com-
ponent, dilated main pancreatic duct), FNA cytology results in-
cluding mucin or cellular atypia, type of surgical resection, and
final diagnosis on surgical pathology. While the AGA guidelines
do not explicitly define “dilated main pancreatic duct,” for the
purposes of this study we utilized a cut-off of ≥5mm, as used
to define “worrisome feature” in the Fukuoka guidelines [16].
Cytology specimens were considered “concerning” if there was
evidence of cytologic atypia, high-grade dysplasia, or adeno-
carcinoma.
Study outcomes and statistical analysis
Patients were categorized into 2 groups (surgery or surveil-
lance) based on what the AGA guidelines would have recom-
mended. Our aim was to evaluate performance characteristics
of the AGA guidelines for identification of PCN with HGD or
cancer.
At each of the participating centers, data from electronic
medical records were entered into a password-protected, de-
identified Microsoft Access database (Microsoft Corporation,
Redmond, WA). The databases were transferred to a centralized
location where the data were merged, compared, and recon-
ciled for accuracy. Descriptive statistics were used to character-
ize the demographics of our population. Continuous data were
summarized using means and standard deviation, and nominal
data were summarized using counts and percentages. We sub-
sequently calculated performance characteristics of the AGA
guidelines for the finding of cancer or high-grade dysplasia on
surgical pathology, including sensitivity, specificity, diagnostic
accuracy, positive and negative predictive values, and positive
and negative likelihood ratios.
Results
A flow chart depicting our results and major findings is shown
in ▶Fig. 1.
Patients undergoing EUS for evaluation 
of PCN from 2004–2014:
3112









Zero high-risk features: 4
One high-risk features: 5
Concerning cytology
Zero high-risk features: 9
One high-risk feature: 15
Two high-risk features: 12
Three high-risk features: 3
Negative cytology
Two high-risk features: 4
Three high-risk features: 2
Patients excluded (2812)









▶ Fig. 1 Flowchart of patient selection and major study results.
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Patient characteristics
A total of 3112 patients underwent EUS for evaluation of a PCN
during the study period, of whom 300 patients were identified
as having undergone surgical resection for PCNs relevant to the
AGA guidelines. Patient demographics are shown in ▶Table 2.
Among the 300 patients who underwent surgical resection,
the average age was 65.2 years and 62.3% were female.
EUS/surgical details
Characteristics of surgical resection are shown in ▶Table3. A
total of 11/300 (3.7%) patients had all 3 high-risk features de-
fined in the AGA guidelines, 42/300 (14.0%) patients had 2
high-risk features, 113/300 (37.7%) patients had 1 high-risk
feature, and 134/300 (44.6%) patients had no high-risk fea-
tures. A total of 98/300 (34.7%) patients had concerning cytol-
ogy findings such as atypia or malignancy, of whom 9 (9.2%)
patients had 3 high-risk features, 21 (21.4%) patients had 2
high-risk features, 36 (36.7%) patients had 1 high-risk feature,
and 32 (32.7%) patients had no high-risk features.
Surgical resection included Whipple pancreaticoduode-
nectomy (127/300, 42.5%), distal pancreatectomy (154/300,
51.5%), middle pancreatectomy (9/300, 3.0%), total pancrea-
tectomy (8/300, 2.7%), and exploratory laparotomy with surgi-
cal biopsy (1/300, 0.3%). The surgical pathology for resected
cystic neoplasms included MCNs (63/300, 21.0%), IPMNs
(198/300, 66.0%), and serous cystadenomas (39/300, 13.0%).
Among surgically resected lesions, none of the 39 serous cysta-
denomas contained adenocarcinoma, while 49/198 (24.7%)
IPMNs contained adenocarcinoma, 2/198 (1.0%) IPMNs con-
tained HGD, and 3/63 (4.8%) MCNs contained adenocarcino-
ma. Serous cystadenomas underwent surgical resection for a
variety of reasons which included unclear diagnosis on preo-
perative EUS, and suspicion of a solid mass in 3 patients.
A total of 54 patients were found to have malignant PCNs,
and their characteristics are shown in ▶Table4. Among these
patients, 45/54 (83.3%) either had evidence of concerning cy-
tology or had 2 or more high-risk features and would have
been recommended for surgery, whereas 9/54 (16.7%) had no
evidence of concerning cytology and fewer than 2 high-risk fea-
tures and would have been recommended for surveillance. Of
note, 15 patients had evidence of concerning cytology with
only 1 high-risk feature, and 9 patients had evidence of con-
cerning cytology only without any high-risk features; had the
AGA guidelines been followed, these 24 patients would have
been recommended for surgery based solely on concerning cy-
tology.
Among the 46 (16.1%) patients found to have a solid cyst
component on EUS, only 26 were confirmed to have IPMNs
with adenocarcinoma, and 1 had IPMN with HGD. The remain-
der included 12 cases of IPMNs without HGD or adenocarcino-
ma, 4 cases of MCNs without adenocarcinoma, and 3 cases of
serous cystadenomas.
Diagnostic performance of AGA guidelines
Overall, the AGA guidelines would have recommended surgery
in 121 (40.3%) patients and surveillance in 179 (59.7%) pa-
tients. Among patients who would have been recommended
for surgery, 45 (37.2%) had cancer/HGD and would have been
appropriately referred, whereas 76 (62.8%) had no evidence of
cancer/HGD. Among patients who would have been recom-
mended for surveillance, 170 (95.0%) had no evidence of can-
cer/HGD and would have been appropriately referred; however,
9 (5.0%) patients had cancer that would have been “missed.”
Overall, for the finding of cancer/HGD on surgical pathology,
the AGA guidelines had a sensitivity of 83.3% (95% confidence
interval [CI] 70.7–92.1), specificity of 69.1% (95% CI 62.9–
74.8), positive predictive value (PPV) of 37.2% (95% CI 28.6–
46.4), negative predictive value (NPV) of 95.0% (95% CI 90.7–
97.7), positive likelihood ratio of 2.70 (95% CI 2.16–3.37),
negative likelihood ratio of 0.24 (95% CI 0.13–0.44), and diag-
nostic accuracy of 71.7% (95% CI 67.4–74.6). ▶Table5 shows
the performance characteristics of the AGA guidelines.
Missed’ cancers
There were no obvious similarities between the 9 “missed” can-
cers except that all had a cyst size ≥1cm. None had a solid com-
ponent or dilated main pancreatic duct ≥5mm on EUS, and
only 5 had a cyst size ≥3cm. Cytology was not performed on 2
▶ Table 2 Demographics.
Incidence (n, %)
Demographics Total patients 300
Age (years, mean ± SD) 62.6 ± 13.8
Gender Male 113 (37.7)
Female 187 (62.3)
Surgery Whipple 127 (42.5)
Distal pancreatectomy 154 (51.5)
Middle pancreatectomy 9 (3.0)
Total pancreatectomy 8 (2.7)
Exploratory Llparotomy 1 (0.3)
Cyst findings IPMN without cancer 147 (49.0)




MCN without cancer 60 (20.0)
MCN with cancer 3 (1.0)
SCA without cancer 39 (13.0)
SCA with cancer 0 (0.0)
Cancer Total cancer 54 (18.0)
IPMN with adenocarcinoma 49 (90.7)
IPMN with high grade
dysplasia
2 (3.7)
MCN with adenocarcinoma 3 (5.6)
IPMN, intraductal papillary mucinous neoplasm; MCN, mucinous cystic
neoplasm; SCA, serous cystadenoma; SD, standard deviation
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patients, was unsatisfactory on 1 patient, and was benign on 6
patients. On surgical pathology, there were 2 MCNs with carci-
noma and 7 IPMNs with carcinoma. The 9 “missed” cancers
were all resected between 2005–2011 (2 in 2006, 3 in 2007,
and 1 each in 2005, 2008, 2009, and 2011). These patients
were referred for surgery based on either change in cyst size
on subsequent cross-sectional imaging at 6 months to 12
months, or based on other factors not included in the AGA
guidelines, such as markedly elevated cyst fluid CEA levels,
being “young and fit” per Fukuoka guidelines, and patient pre-
ferences.
If our definition of “concerning” cytology had been changed
to a strict definition, which only included unequivocal findings
of high-grade dysplasia or adenocarcinoma, the performance
of the AGA guidelines would have been less robust. There
would have been 21 “missed” cancers, representing 11.7% of
patients who would have been referred for surveillance. The
specificity would have been 85.4% (95% CI 80.3–89.5), sensi-
▶ Table 3 Outcomes in patients undergoing surgical resection for pancreatic cystic neoplasms.
Total n=300 Incidence (n, %)
AGA high-risk features Cyst size ≥30mm 130 (43.3)
Main pancreatic duct size≥5mm 54 (30.2)
Solid mass 46 (16.1)
Concerning cytology (cellular atypia, HGD, or cancer) 98 (34.7)
Number of AGA high-risk features 0 features 134 (44.6)
1 feature 113 (37.7)
2 features 42 (14.0)
3 features 11 (3.7)
AGA guidelines recommend surveillance 0 features + negative cytology 102 (34.0)
1 feature + negative cytology 77 (25.7)
Total surveillance 179 (59.7)
AGA guidelines recommend surgery 0 features + concerning cytology 32 (10.7)
1 feature + concerning cytology 36 (12.0)
2 features + negative cytology 21 (7.0)
2 features + concerning cytology 21 (7.0)
3 features + negative cytology 2 (0.7)
3 features + concerning cytology 9 (3.0)
Total surgery 121 (40.3)
▶ Table 4 Patients with malignant pancreatic cystic neoplasms.
Total n=54 Incidence (n, %)
AGA guidelines recommend surveillance 0 features + negative cytology 4 (7.4)
1 feature + negative cytology 5 (9.3)
Total surveillance 9 (16.7)
AGA guidelines recommend surgery 0 features + concerning cytology 9 (16.7)
1 feature + concerning cytology 15 (27.8)
2 features + negative cytology 4 (7.4)
2 features + concerning cytology 12 (22.2)
3 features + negative cytology 2 (3.7)
3 features + concerning cytology 3 (5.6)
Total surgery 45 (83.3)
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tivity 61.1% (95% CI 46.9–74.1), PPV 47.8% (95% CI 35.7–
60.2), and NPV 90.9% (95% CI 86.4–94.3).
Discussion
PCNs present a significant dilemma for both patients and provi-
ders due to the risk of malignancy at time of diagnosis, variable
risk of malignancy over time, and significant morbidity and po-
tential mortality associated with surgical resection [7, 9]. De-
spite the role of cross-sectional imaging and EUS-FNA, it con-
tinues to be challenging to accurately differentiate between
PCNs and apply surveillance protocols [10, 11]. Prior consensus
guidelines, including the 2006 Sendai guidelines and the 2012
Fukuoka guidelines, have remained imperfect owing to the low
quality of evidence used to develop them [15–17]. After per-
forming a technical review of the literature [25], the AGA pub-
lished guidelines for management of asymptomatic PCNs [26]
call for a much less aggressive surveillance regimen than the
Fukuoka guidelines. The 2015 AGA guidelines have been re-
garded as controversial due to their mostly conditional recom-
mendations and overall low quality of evidence despite an ex-
tensive technical review [27–30].
In this multicenter retrospective study, we evaluated per-
formance of the AGA guidelines in a large cohort of patients
with surgically confirmed pathology. Cystic degeneration of
pancreatic ductal adenocarcinomas, cystic neuroendocrine tu-
mors, solid pseudopapillary neoplasms, and main duct IPMNs
were not included in our study, because these lesions are typi-
cally recommended to undergo surgery and are not addressed
by the AGA guidelines. In our evaluation of 300 patients who
underwent surgical resection for PCNs relevant to the AGA
guidelines, adherence to these guidelines reduced the number
of patients who would have undergone surgical resection by
approximately 60%.
This reduction in patients referred for surgery is due to the
fact that only 53/300 (17.7%) patients met 2 or more high-risk
features as classified by the AGA guidelines, and only 98/300
(34.6%) patients had concerning cytology findings. The AGA
guidelines would have recommended surgery in only 121/300
(40.3%) patients, in whom only 45 cysts harbored adenocarci-
noma or HGD on surgical pathology. Notably, 21/45 (46.7%)
cysts demonstrated 2 or more high-risk features with or with-
out concerning cytology findings, whereas the remaining 24
(53.3%) cysts had fewer than 2 high-risk features but had con-
cerning cytology findings. This suggests that the use of 2 or
more high-risk features alone per the AGA guidelines is insuffi-
cient, and that there remains a role for EUS and cytology, de-
spite its reportedly poor sensitivity [11]. In addition, in clinical
practice these patients also often had other EUS findings or pa-
tient-specific factors that led to surgical referral. Given that the
definitions for “concerning” cytology are highly variable, this
finding demonstrates that cytology results can dramatically in-
fluence the clinical decision for surgery versus surveillance. To
highlight this issue, “atypical” cytology was used in our study
given that in our clinical experience, “atypical” cytology results
are often accompanied by additional commentary from the pa-
thologist such as “cannot rule out” advanced dysplasia or well-
differentiated adenocarcinoma.
Our study validates the major strengths of the AGA guide-
lines in that approximately 60% of patients would have been
spared from undergoing surgical resection, with a high sensitiv-
ity (83.3%) and NPV (95.0%). However, despite the apparent
advantage in the accurate triage of low-risk PCNs, the AGA
guidelines remain imperfect. Of the cysts with fewer than 2
high-risk features and no evidence of concerning cytology,
▶ Table 5 Performance characteristics of 2015 AGA guidelines.
Results using 2015 AGA guidelines
n= 300 patients Cancer found (n =54, %) No Cancer (n = 246, %)
Recommend surgery
(n =121)
45 (37.2) 76 (62.8)
Recommend surveillance
(n =179)
9 (5.0) 170 (95.0)
Performance characteristics for finding of
cancer/HGD on surgical pathology




Positive predictive value 37.2 (28.6–46.4)
Negative predictive value 95.0 (90.7–97.7)
Positive likelihood ratio 2.70 (2.16–3.37)
Negative likelihood ratio 0.24 (0.13–0.44)
Accuracy 71.7 (67.4–74.6)
HGD, high-grade dysplasia
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which would have been triaged to surveillance per the AGA
guidelines, 9 cancers would have been “missed.” Interestingly,
all 9 patients had their tumors resected prior to 2011, although
4 would have been missed under the Sendai guidelines. Our re-
sults may actually underestimate the true performance charac-
teristics of the AGA guidelines, specifically with regards to sen-
sitivity and NPV given advances in imaging technology over our
10-year study period.
A recent retrospective study suggested that both the origi-
nal Sendai guidelines and the Fukuoka guidelines are able to ac-
curately determine which patients with pancreatic cysts have
advanced neoplasia, with the Sendai guidelines demonstrating
91.7% sensitivity, 21.5% specificity, 21% PPV, and 91.9% NPV
for identification of advanced neoplasia [24]. However, as dem-
onstrated in prior studies [19], several patients with high-grade
dysplasia were missed. While we did not directly compare the
AGA, Sendai, and Fukuoka guidelines, the observation that the
9 cancers in our surgical cohort were triaged to surveillance by
the AGA guidelines but resected per the Sendai guidelines at-
tests to the higher sensitivity but lower specificity of the Sendai
guidelines.
Our study follows several others that have been published
evaluating the AGA guidelines. Singhi et al reported a retro-
spective study of the AGA guidelines applied to 225 patients
with pancreatic cystic lesions, of whom only 41 patients had
surgical pathology [31]. Notably, 45% of IPMNs with HGD or
adenocarcinoma were triaged to surveillance. Among all pan-
creatic cysts, the AGA guidelines had 62% sensitivity, 79% spe-
cificity, 57% PPV, and 87% NPV for identification of advanced
neoplasia. Similarly, Ma et al reported in a retrospective study
that the AGA guidelines did not appear to be superior to Fukuo-
ka in identifying advanced neoplasia in suspected PCNs [32]. In
their study, both guidelines had PPV of 71% to 74% and would
lead to unnecessary resections in patients without advanced
neoplasia, while missing additional cases with advanced neo-
plasia. The precise reasons for discordance among studies are
unclear and may be due to differences in study populations
and data analysis.
Prior studies evaluating the Sendai and Fukuoka guidelines
have suggested that although cyst surveillance is cost-effective
when compared to no surveillance or immediate surgery [33],
ongoing cyst surveillance still confers significant additional
costs to society when applied to large populations of patients
who have asymptomatic PCNs [28]. While a formal cost analysis
was not performed as part of this study, adherence to the AGA
guidelines would have likely resulted in substantial cost savings
given that almost 60% of patients would have been triaged to
surveillance rather than surgical resection.
There are several limitations of this study that merit discus-
sion. The majority of our patients were referred from outside
institutions and therefore follow-up was limited. The retrospec-
tive nature of our study also made it impossible to determine
how many of our patients were truly asymptomatic. Further-
more, the natural history of those patients recommended to
undergo surveillance by the AGA guidelines is not known, as all
patients underwent surgical resection.
Importantly, our study population was highly selected to in-
clude only those patients who underwent EUS and subsequent-
ly had surgical resection for non-main duct IPMNs, MCNs, and
SCAs. While these are the lesions that were specifically addres-
sed by the AGA guidelines, we acknowledge that often the pa-
thology is not known until surgical resection, and the AGA
guidelines also do not recommend EUS for every patient.
Nevertheless, by biasing our study population away from the
lowest- and highest-risk lesions, both of which would have
never undergone EUS, we are still able to demonstrate that
only 5% of patients recommended to undergo surveillance
were found to have cancer on pathology. This finding suggests
that when the AGA guidelines are applied to a broader popula-
tion of predominantly low-risk asymptomatic PCNs, the actual
rate of missed cancer is likely much lower. Furthermore, al-
though 5% of patients recommended to undergo serial surveil-
lance were ultimately found on pathology to have cancer, this
does not necessarily imply outright missing a diagnosis of can-
cer, as these PCNs would have potentially developed changes or
concerning features on surveillance that would prompt surgical
referral.
Conclusion
In conclusion, in our large multicenter surgical cohort, adher-
ence to the 2015 AGA guidelines would have resulted in nearly
60% fewer patients being referred for surgical resection and ac-
curately recommended surveillance for most patients with
asymptomatic PCNs. However, a malignancy was identified in
5% of patients for whom surveillance was recommended, al-
though these cases may have been subsequently identified dur-
ing surveillance. Our study was specifically performed as an au-
dit of real world clinical practice at multiple major academic in-
stitutions, and highlights a continued role for EUS-FNA in the
management of a select population of higher-risk PCNs. While
current studies are exploring molecular markers [31, 34], as
well as developing nomograms for predicting the probability
of high-risk PCNs [35], our data emphasize the continued need
to individualize treatment of PCNs until additional higher-qual-
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